Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Robson

Showing results (231-240 of 352) with videos related to

Pageof 36
Sort By:
Plos One|May 4, 2010
Genetic analysis of the early natural history of epithelial ovarian carcinomaBhavana Pothuri, Mario M Leitao, Douglas A Levine, et al.
The New England Journal of Medicine|May 25, 2002
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutationNoah D Kauff, Jaya M Satagopan, Mark E Robson, et al.
The American Journal of Surgical Pathology|June 11, 2021
PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical AssaysAnne Grabenstetter, Achim A Jungbluth, Denise Frosina, et al.
The Oncologist|September 22, 2011
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directionsMaeve A Lowery, David P Kelsen, Zsofia K Stadler, et al.
Breast Cancer Research and Treatment|February 3, 2017
Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancerJada G Hamilton, Margaux C Genoff, Melissa Salerno, et al.
Patient Education and Counseling|June 18, 2010
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimatesSandra M Brown, Julie O Culver, Kathryn E Osann, et al.
JCO Precision Oncology|September 13, 2019
Patients' Medical and Psychosocial Experiences After Detection of a <i>CDH1</i> Variant With Multigene Panel TestingJada G Hamilton, Jessica M Long, Amanda C Brandt, et al.
Cancer Cell|August 15, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerJuan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
JNCI Cancer Spectrum|July 31, 2019
The Landscape of Somatic Genetic Alterations in Breast Cancers from <i>CHEK2</i> Germline Mutation CarriersDiana Mandelker, Rahul Kumar, Xin Pei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang, Gabriella M D'Andrea, Mary E Moynahan, et al.
Pageof 36

Showing results (231-240 of 352) with videos related to

Sort By:
Pageof 36
Plos One|May 4, 2010
Genetic analysis of the early natural history of epithelial ovarian carcinomaBhavana Pothuri, Mario M Leitao, Douglas A Levine, et al.
The New England Journal of Medicine|May 25, 2002
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutationNoah D Kauff, Jaya M Satagopan, Mark E Robson, et al.
The American Journal of Surgical Pathology|June 11, 2021
PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical AssaysAnne Grabenstetter, Achim A Jungbluth, Denise Frosina, et al.
The Oncologist|September 22, 2011
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directionsMaeve A Lowery, David P Kelsen, Zsofia K Stadler, et al.
Breast Cancer Research and Treatment|February 3, 2017
Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancerJada G Hamilton, Margaux C Genoff, Melissa Salerno, et al.
Patient Education and Counseling|June 18, 2010
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimatesSandra M Brown, Julie O Culver, Kathryn E Osann, et al.
JCO Precision Oncology|September 13, 2019
Patients' Medical and Psychosocial Experiences After Detection of a <i>CDH1</i> Variant With Multigene Panel TestingJada G Hamilton, Jessica M Long, Amanda C Brandt, et al.
Cancer Cell|August 15, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerJuan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
JNCI Cancer Spectrum|July 31, 2019
The Landscape of Somatic Genetic Alterations in Breast Cancers from <i>CHEK2</i> Germline Mutation CarriersDiana Mandelker, Rahul Kumar, Xin Pei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang, Gabriella M D'Andrea, Mary E Moynahan, et al.
Pageof 36